High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Internal Medicine

• Publication date

  2004-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.7326/0003-4819-140-2-200401200-00008PMID 14734330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stem cell transplantation for the management of primary systemic amyloidosis.

  2002cited by this paper
• A multicenter phase II trial of 4′-iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)

  2002cited by this paper
• AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation

  2002cited by this paper
• Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.

  2002influential reference
• Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.

  2001cited by this paper
• Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.

  2001cited by this paper
• Effect of Dose-Intensive Intravenous Melphalan and Autologous Blood Stem-Cell Transplantation on AL AmyloidosisAssociated Renal Disease

  2001cited by this paper
• An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis

  2001cited by this paper
• Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)

  2000cited by this paper
• Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report

  2000cited by this paper
• Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis

  1999cited by this paper
• High-dose melphalan and stem cell rescue for AL amyloidosis

  1999cited by this paper
• Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.

  1999cited by this paper
• Phase II trial of high‐dose dexamethasone for previously treated immunoglobulin light‐chain amyloidosis

  1999cited by this paper
• Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

  1998cited by this paper
• Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

  1998cited by this paper
• Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.

  1998cited by this paper
• The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

  1998cited by this paper
• Mobilized CD34+ cells selected as autografts in patients with primary light‐chain amyloidosis: rationale and application

  1998cited by this paper
• Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.

  1997cited by this paper
• The systemic amyloidoses.

  1997cited by this paper
• A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

  1997cited by this paper
• Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

  1997cited by this paper
• High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement.

  1996cited by this paper
• Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.

  1996cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

  1996cited by this paper
• Intermediate‐dose melphalan (IDM) combined with G‐CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma

  1996cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper
• Autologous and allogeneic transplants for multiple myeloma.

  1995cited by this paper
• Treatment of primary amyloidosis.

  1995cited by this paper
• Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

  1995cited by this paper
• New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin.

  1995cited by this paper
• The epidemiology of AL and AA amyloidosis.

  1994cited by this paper
• High-dose therapy and autologous transplantation in amyloidosis-AL.

  1993cited by this paper
• Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.

  1992cited by this paper
• Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.

  1985cited by this paper
• Amyloidosis (AL). Clinical and laboratory features in 229 cases.

  1983cited by this paper
• Amyloidosis (AL). Clinical and laboratory features in 229 cases.

  1983cited by this paper
• Amyloidosis: review of 236 cases.

  1975cited by this paper

• AL Amyloidosis Patients Continue to Benefit from HDCT/ASCT Consolidation in the Daratumumab Era.

  2026cites this paper
• A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis

  2025influential citation
• Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis

  2025influential citation
• Clinicopathological study of renal amyloidosis and its relationship with renal amyloid prognostic score

  2025cites this paper
• Heart Transplantation for Cardiac Amyloidosis: Mayo Clinic Consensus Statement.

  2025cites this paper
• Multisystem Light Chain Amyloidosis: Diagnostic and Therapeutic Challenges

  2025cites this paper
• 18F-Florbetaben PET/CT for the Diagnosis and Subtyping of Cardiac Amyloidosis: A Case Series and Review of the Literature.

  2024cites this paper
• Treatment of AL amyloidosis in the era of novel immune and cellular therapies

  2024cites this paper
• Acute kidney injury during autologous stem cell transplantation in light chain amyloidosis with kidney involvement and their impact on prognosis

  2024cites this paper
• A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots

  2024cites this paper
• Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management

  2024cites this paper
• Amyloidosis in Childhood: A Review of Clinical Features and Comparison with Adult Forms

  2024cites this paper
• Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis

  2024cites this paper
• Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis.

  2024cites this paper
• Autologous stem cell transplantation in AL amyloidosis: Muddy waters.

  2024cites this paper
• Automated Neural Architecture Search for Cardiac Amyloidosis Classification from [18F]-Florbetaben PET Images

  2024cites this paper
• Amyloidosis of the Heart: A Comprehensive Review

  2023cites this paper
• Paradoxical Left Ventricular Hypertrophy by Echocardiogram and Low Voltage ECG: A Key Clue in the Diagnostic Workup of Two Distinct Presentations of Cardiac AL Amyloidosis

  2023cites this paper
• Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a phase II study: Propylene Glycol-Free Melphalan Conditioning for Autologous Stem Cell Transplantation for AL Amyloidosis.

  2023cites this paper
• Severe cardiac AL amyloidosis in an elderly patient with multiple SARS-CoV-2 reinfection: a case report

  2023cites this paper
• Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• A Short Review of Hematopoietic Transplantation for AL Amyloidosis

  2022cites this paper
• Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

  2022cites this paper
• State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond

  2022cites this paper
• Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

  2022cites this paper
• Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis

  2022cites this paper
• Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis

  2022cites this paper
• Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea.

  2022cites this paper
• Heart transplantation in cardiac amyloidosis

  2022cites this paper
• Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis

  2022cites this paper
• Health‐related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study

  2022cites this paper
• Outcomes of heart transplantation in cardiac amyloidosis: an updated systematic review

  2022cites this paper
• Beyond Survival in AL amyloidosis: Identifying and Satisfying Patients’ Needs

  2022cites this paper
• Pulmonary amyloidosis with tracheobronchial presentation: clinical case report Amiloidose

  2022cites this paper
• Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis.

  2021cites this paper
• Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.

  2021cites this paper
• Retrospective analysis of autologous stem cell transplantation for AL amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

  2021cites this paper
• The Clinical Characteristics of Immunoglobulin Light Chain Amyloidosis in the Chinese Population: A Systematic Scoping Review (Preprint)

  2021cites this paper
• Primary Restrictive, Infiltrative, and Storage Cardiomyopathies

  2021cites this paper
• Cardiac Amyloidosis in a Patient Presenting with Symptoms of Heart Failure

  2021cites this paper
• The Clone Wars: Diagnosing and Treating Dysproteinemic Kidney Disease in the Modern Era

  2021cites this paper
• Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images

  2021cites this paper
• Recent advances in the diagnosis and management of amyloid cardiomyopathy

  2021cites this paper
• [AL-amyloidosis with cardiac involvement. Diagnostic capabilities of non-invasive methods].

  2021cites this paper
• Does protein aggregation drive postmitotic tissue degeneration?

  2021cites this paper
• Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.

  2021cites this paper
• Systemic Disease and the Skin

  2021cites this paper
• Long-term outcomes of kidney transplantation in patients with AL amyloidosis from The Mayo Clinic

  2021cites this paper
• A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis

  2021cites this paper
• The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis

  2020cites this paper
• High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis

  2020cites this paper
• The prognostic value of right ventricular deformation derived from cardiac magnetic resonance tissue tracking for all-cause mortality in light-chain amyloidosis patients.

  2020cites this paper
• Solid Organ Transplantation.

  2020cites this paper
• 18F-fluoride PET/MR in cardiac amyloid: A comparison study with aortic stenosis and age- and sex-matched controls

  2020cites this paper
• Multimodality imaging in cardiac amyloidosis: a primer for cardiologists.

  2020cites this paper
• Significant role of magnetic resonance imaging for the diagnosis and evaluation of cardiac amyloidosis in primary light chain amyloidosis

  2020cites this paper
• Successful treatment of a unique case of congophilic fibrillary glomerulonephritis

  2020cites this paper
• Renal amyloidosis: validation of a proposed histological scoring system in an independent cohort

  2020cites this paper
• A Rare Case of Cerebral Amyloidoma Mimicking a Hemorrhagic Malignant Central Nervous System Neoplasm

  2020cites this paper
• A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.

  2020cites this paper
• Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis.

  2020cites this paper
• Kidney Transplantation in Systemic Amyloidosis

  2020cites this paper
• The Clinicopathologic Features and the Factors Associated with the Survival in Light -Chain Amyloidosis Patients: A Single Center Descriptive Study

  2020cites this paper
• Autologous stem cell transplantation in light-chain amyloidosis

  2020cites this paper
• Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis.

  2020cites this paper
• A pharmacist’s review of the treatment of systemic light chain amyloidosis

  2020influential citation
• Trends, burden, and impact of arrhythmia on cardiac amyloid patients: A 16‐year nationwide study from 1999 to 2014

  2020cites this paper
• Successful treatment of gamma 1 heavy chain deposition disease with bortezomib and dexamethasone

  2019cites this paper
• AL Amyloidosis for the Cardiologist and Oncologist

  2019cites this paper
• Neuropathy Associated with Systemic Amyloidosis

  2019cites this paper
• Title Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma : a case report

  2019cites this paper
• Seminal Cell-Free DNA Test for the Management of Male Infertility

  2019cites this paper
• Cardiac Interventional Procedures in Cardio-Oncology Patients.

  2019cites this paper
• Amyloidosis: Systems-Based Therapies

  2019cites this paper
• 99mTc-aprotinin imaging in cardiac amyloidosis. Make an old tool new again?

  2019cites this paper
• Systemic Amyloidosis: a Contemporary Overview

  2019cites this paper
• Prognostic impact of light-chain and transthyretin-related categories in cardiac amyloidosis: A systematic review and meta-analysis.

  2019cites this paper
• A 24‐year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom

  2019cites this paper
• Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach

  2019cites this paper
• Interventional Cardiology in the Cancer Patient

  2019cites this paper
• Low voltage criteria EKG as a harbinger of systemic disease

  2019cites this paper
• Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.

  2019cites this paper
• Prognostic values of novel biomarkers in patients with AL amyloidosis

  2019cites this paper
• PS1373 A TWENTY-FOUR YEAR EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN AMYLOIDOSIS PATIENTS IN THE UNITED KINGDOM

  2019cites this paper
• A Patient Presenting with Severe Hypoglycaemia and Autonomic Instability Found to Have Multiple Myeloma Complicated with Amyloidosis

  2019cites this paper
• Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.

  2019cites this paper
• Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease

  2019influential citation
• Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis

  2019cites this paper
• Long-term outcome of kidney transplantation in AL amyloidosis.

  2019cites this paper
• Health Risk Behavior amongst Adolescents in Relation to Impulsivity

  2019cites this paper
• High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators

  2019cites this paper
• Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis

  2019cites this paper
• Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

  2019cites this paper
• New developments in diagnosis, risk assessment and management in systemic amyloidosis.

  2019cites this paper
• Light Chain (AL) Amyloidosis and the Kidney

  2018cites this paper
• Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

  2018cites this paper
• Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.

  2018cites this paper
• High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers

  2018cites this paper
• Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis

  2018cites this paper
• Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis – A Single Institution 11 Year Experience

  2018cites this paper